Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis
Molecular Psychiatry · 2024-08 · 29 (8) · 2389-2398
DOI: 10.1038/s41380-024-02457-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Psychiatry, online erschienen am 15.03.2024. Verfasst von Tracy L Warren und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Physiology and Behavior, University of California, Davis, CA, USA. Hauptthemen laut MEDLINE: Multifactorial Inheritance, Psychotic Disorders, Bipolar Disorder, Schizophrenia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH), NIMH NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
A primary goal of psychiatry is to better understand the pathways that link genetic risk to psychiatric symptoms. Here, we tested association of diagnosis and endophenotypes with overall and neurotransmitter pathway-specific polygenic risk in patients with early-stage psychosis. Subjects included 205 demographically diverse cases with a psychotic disorder who underwent comprehensive psychiatric and neurological phenotyping and 115 matched controls. Following genotyping, we calculated polygenic scores (PGSs) for schizophrenia (SZ) and bipolar disorder (BP) using Psychiatric Genomics Consortium GWAS summary statistics. To test if overall genetic risk can be partitioned into affected neurotransmitter pathways, we calculated pathway PGSs (pPGSs) for SZ risk affecting each of four major neurotransmitter systems: glutamate, GABA, dopamine, and serotonin. Psychosis subjects had elevated SZ PGS versus controls; cases with SZ or BP diagnoses had stronger SZ or BP risk, respectively. There was no significant association within psychosis cases between individual symptom measures and overall PGS. However, neurotransmitter-specific pPGSs were moderately associated with specific endophenotypes; notably, glutamate was associated with SZ diagnosis and with deficits in cognitive control during task-based fMRI, while dopamine was associated with global functioning. Finally, unbiased endophenotype-driven clustering identified three diagnostically mixed case groups that separated on primary deficits of positive symptoms, negative symptoms, global functioning, and cognitive control. All clusters showed strong genome-wide risk. Cluster 2, characterized by deficits in cognitive control and negative symptoms, additionally showed specific risk concentrated in glutamatergic and GABAergic pathways. Due to the intensive characterization of our subjects, the present study was limited to a relatively small cohort. As such, results should be followed up with additional research at the population and mechanism level. Our study suggests pathway-based PGS analysis may be a powerful path forward to study genetic mechanisms driving psychiatric endophenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurobiology, Physiology and Behavior, University of California, Davis, CA, USA.
- Department of Psychiatry and Behavioral Sciences, University of California, Davis, CA, USA.
- Center for Neuroscience, University of California, Davis, CA, USA.
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR.
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
- Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Tracy L Warren, Tyler A Lesh, Vanessa Zarubin, Alex S Nord
Förderung
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- NIMH NIH HHS
- NIGMS NIH HHS
- NINDS NIH HHS
- UC | University of California, Davis (UC Davis)
Zitieren
APA
Warren, T. L., Tubbs, J. D., Lesh, T. A., Corona, M. B., Pakzad, S. S., Albuquerque, M. D., Singh, P., Zarubin, V., Morse, S. J., Sham, P. C., Carter, C. S., & Nord, A. S. (2024). Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis. Molecular Psychiatry, 29(8), 2389-2398. https://doi.org/10.1038/s41380-024-02457-0
Vancouver
Warren TL, Tubbs JD, Lesh TA, Corona MB, Pakzad SS, Albuquerque MD, et al. Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis. Molecular Psychiatry. 2024;29(8):2389-2398. doi:10.1038/s41380-024-02457-0
BibTeX
@article{Warren2024,
author = {Warren, Tracy L and Tubbs, Justin D and Lesh, Tyler A and Corona, Mylena B and Pakzad, Sarvenaz S and Albuquerque, Marina D and Singh, Praveena and Zarubin, Vanessa and Morse, Sarah J and Sham, Pak Chung and Carter, Cameron S and Nord, Alex S},
title = {Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis},
journal = {Molecular Psychiatry},
year = {2024},
volume = {29},
number = {8},
pages = {2389--2398},
doi = {10.1038/s41380-024-02457-0}
}
EUVIMED